Recent Updates
Recently added Catalysts

PhXA41

Phase 3

Glaucoma | Small molecule | Ophthalmology |Pfizer, Inc.|Last Updated: Mar 25, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment268

FDA Designations

No designations recorded

Clinical trial landscape

PhXA41 · 1 trial · 3 indications

Phase 3 1
NCT00751127A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular HypertensionGlaucoma
COMPLETED268 Analytics
PHASE3COMPLETED
A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension
Glaucoma
NCT00751127268
Unlock trial analytics

Study Endpoints

Primary Endpoints

to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment.
6 mos

Secondary Endpoints

to describe the IOP development throughout the study period and to follow the safety variables in the two treatment groups.
6 mos
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TimololACTIVE_COMPARATOR -
PhXA41EXPERIMENTAL -

Interventions

NameTypeDescription
PhXA41DRUGOne drop in the affected eye once daily for six months.
timololDRUGOne drop in the affected eye twice daily for six months.
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites17

Inclusion Criteria: * Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension. * Open angle glaucoma appearing more than 6 months after cataract surgery is recognized as primary open angle glaucoma. (individuals requiring treatment bilatera...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Glaucoma 28 trials

CompanyTickerTrialsLead PhaseDrugs
Glaukos CorpGKOS6PHASE3Gen 2 Travoprost Intracameral, Timolol eye 0.5%
AbbVie, Inc.ABBV2PHASE3Undisclosed
SpyGlass Pharma, Inc.SGP4PHASE3Bimatoprost System, Timolol, 0.5%
Amneal Pharmaceuticals, Inc. Class AAMRX2PHASE3Test- Bimatoprost 0.01%, Reference- LUMIGAN
Alcon AGALC5N/AUndisclosed
Sight Sciences, Inc.SGHT3N/AUndisclosed
Unlock Competitive Intelligence

Frequently asked questions about PhXA41

What is PhXA41 used for?

PhXA41 is an investigational small molecule being developed for the treatment of glaucoma, specifically open angle glaucoma and ocular hypertension. It is administered as an ophthalmic solution and is currently in Phase 3 clinical development.

What does PhXA41 target?

PhXA41 is a prostaglandin analog that works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. This mechanism helps to lower pressure in the eye, which is the primary goal in treating glaucoma and ocular hypertension.

Who makes PhXA41?

PhXA41 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with glaucoma.

What phase is PhXA41 in?

PhXA41 is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is being evaluated for the treatment of glaucoma.

What clinical trials is PhXA41 in?

PhXA41 has been studied in one completed Phase 3 clinical trial, NCT00751127. This was a 6-month, randomized, double-blind, active-controlled study comparing latanoprost with timolol in 268 patients with open angle glaucoma or ocular hypertension in the United States.

Is PhXA41 the same as latanoprost?

PhXA41 is the chemical name for latanoprost, a prostaglandin analog used to lower intraocular pressure. In the clinical trial, PhXA41 was compared against timolol, another glaucoma medication, to assess its efficacy and safety.